Results 131 to 140 of about 5,494 (193)

Evaluating the safety of investigational anti-Alzheimer's drugs: a comprehensive meta-analysis in the past to current decade. [PDF]

Dement Neuropsychol
Shaik NS, Balya H, Ramamurthy S, Pandiyan B, Elias JM, Gunturu S.   +5 more
europepmc   +1 more source

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now? [PDF]

Int J Mol Sci
Higgins M, Wasef V, Kwakowsky A.
europepmc   +1 more source

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study. [PDF]

Front Pharmacol
Geerts H, Short SM, Grant A, van der Graaf PH.   +3 more
europepmc   +1 more source

Structural and Functional Determinants of ARIA-H Risk in Anti-Amyloid Monoclonal Antibodies: A Comparative Mechanistic Framework for Alzheimer's Immunotherapy Development. [PDF]

Curr Neuropharmacol
An D, Zou X, Xu Y.
europepmc   +1 more source

Advances in modified anti-Aβ antibodies for the treatment of Alzheimer's disease. [PDF]

BMC Med
Li S, Gu J, Xu Z, He C, Yu C.
europepmc   +1 more source

Network meta-analysis of the efficacy of nine drugs for cognitive function in patients with Alzheimer's disease. [PDF]

J Alzheimers Dis Rep
Huang S, Guo Y.
europepmc   +1 more source

Landscape of Apolipoprotein (APOE) in the Emirati Population and Recommendations for a Genotyping Approach for Amyloid-Beta Monoclonal Antibodies (Aβ-mAbs) in Alzheimer's Disease Patients. [PDF]

Cureus
Mohammed W, Al Ameri M, Al Marzooqi S, Alsafar H, Olbrich R, Mousa M, Barayan D, Magalhaes T, Quilez J, Reche J, Alkaf B, Shatila A, Marzouka NAD, Iqbal I, Yousif A, Rahma A, Al Mannaie A.   +16 more
europepmc   +1 more source

The highest clinical trial failure rate for any disease in modern medicine: How both amyloid- and non-amyloid-targeting therapies failed to alter disease course in Alzheimer's disease. [PDF]

Free Neuropathol
Guth MAS.
europepmc   +1 more source